Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ingenew Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients.
Product Name : Hesperco
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ingenew Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma Files Natural Product License with Health Canada for Bioflavonoid Formulation, Hesperco
Details : Valeo Pharma has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Product Name : HesperCo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable